Pot Stock Weakness Scuttles MedMen’s Acquisition of PharmaCann
(Bloomberg) -- The weakness in pot stocks has scuttled MedMen Enterprises Inc.'s planned acquisition of PharmaCann LLC less than a month after it received antitrust approval.
The Los Angeles-based cannabis company said Tuesday that it will terminate the all-share deal, which was valued at $682 million when it was announced last October and MedMen was trading at about $4.45 a share. Cannabis shares have tumbled since then, with the Horizons Marijuana Life Sciences Index ETF down about 50% and MedMen's stock down 65% to $1.52.
“The cannabis sector has evolved tremendously since we first announced the PharmaCann transaction and based on the current macro environment and future opportunities that exist for our business, we believe it is now in the best interest of our shareholders to deepen, rather than widen, our company's reach,” MedMen Chief Executive Officer Adam Bierman said in a statement.
MedMen shares fell as much as 9.6% in early trading Tuesday.
The move comes as a surprise, as MedMen said last month that it had received antitrust approval for the deal after a waiting period expired. It was one of the first of several U.S. cannabis mergers that were under Department of Justice review to get the green light, and MedMen said then it expected the acquisition to close by the end of 2019.
The regulatory hurdles delayed the realization of synergies that were initially factored into the value of the deal, MedMen said Tuesday.
As part of the termination, PharmaCann will transfer cannabis licenses and related assets in Illinois and Virginia to MedMen for no additional consideration other than the forgiveness of $21 million of debt, the companies said.
The recent underperformance of cannabis stocks has “made it increasingly more critical to allocate capital efficiently” and some of PharmaCann's assets required significant expenditures, MedMen said Tuesday. It added that it has decided to increasingly focus on the California market, where it plans to have 30 stores open by the end of 2020.
MenMen also announced Tuesday that it has appointed Zeeshan Hyder, formerly its chief corporate development officer, as chief financial officer. Hyder succeeds Michael Kramer, whose employment was terminated on Monday, MedMen said.
To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.net
To contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Steven Fromm, Jacqueline Thorpe
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.